Expanding anti-CD38 immunotherapy for lymphoid malignancies

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, June 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

So far, Altmetric has seen 8 X posts from 5 X users, with an upper bound of 7,001 followers.

𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐚𝐧𝐭𝐢-𝐂𝐃𝟑𝟖 #𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐥𝐲𝐦𝐩𝐡𝐨𝐢𝐝 𝐦𝐚𝐥𝐢𝐠𝐧𝐚𝐧𝐜𝐢𝐞𝐬 Full text 👇 https://t.co/y6eTFuhmxl #MultipleMyeloma #NonHodgkinLymphoma #CART

RT @JournalofExper1: New!💣 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐚𝐧𝐭𝐢-𝐂𝐃𝟑𝟖 #𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐥𝐲𝐦𝐩𝐡𝐨𝐢𝐝 𝐦𝐚𝐥𝐢𝐠𝐧𝐚𝐧𝐜𝐢𝐞𝐬 Full text 👇 https://t.co/nPxQxQEktY #MultipleMye…

New!💣 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐚𝐧𝐭𝐢-𝐂𝐃𝟑𝟖 #𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐥𝐲𝐦𝐩𝐡𝐨𝐢𝐝 𝐦𝐚𝐥𝐢𝐠𝐧𝐚𝐧𝐜𝐢𝐞𝐬 Full text 👇 https://t.co/nPxQxQEktY #MultipleMyeloma #NonHodgkinLymphoma #CART @IREISGufficiale https://t.co/j6qKrM76ND

Expanding anti-CD38 immunotherapy for lymphoid malignancies by Xu Wang https://t.co/I1ryJmGB7G

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.